The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-19. Anything still debated is marked as such rather than presented as settled.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Salvia divinorum is native to the Sierra Mazateca in Oaxaca, Mexico, where it is still used by the Mazatec, primarily to facilitate shamanic visions in the context of curing or divination. S. divinorum is one of several plant species with hallucinogenic properties that are ritually used by Mazatec shamans. In their rituals, the shamans use only freshly harvested S. divinorum leaves. They see the plant as an incarnation of the Virgin Mary, and begin the ritual with an invocation to Mary, Saint Peter, the Holy Trinity, and other saints. Ritual use traditionally involves being in a quiet place after ingestion of the leaf—the Maztec shamans say that "La Maria (S. divinorum) speaks with a quiet voice." It is also used in smaller amounts, as a diuretic, and to treat ailments including diarrhea, anemia, headaches, rheumatism, and a semi-magical disease known as panzón de borrego, or a swollen belly (literally, "lamb belly"). The history of the plant is not well known, and there has been no definitive answer to the question of its origin. Speculation includes Salvia divinorum being a wild plant native to the area; a cultigen of the Mazatecs; or a cultigen introduced by another Indigenous group. Botanists have also not been able to determine whether it is a hybrid or a cultigen.
Selegiline has been limitedly studied in large animals like horses and its dosage in these animals has not been established. In preliminary research, a dose of selegiline of 30 mg orally or intravenously in horses had no observable effects on behavior or locomotor activity. The doses of selegiline used in animals are described as extremely high relative to those used in humans (which are ~0.1 mg/kg body weight).
=== June === 2 June – China successfully lands Chang'e 6 on the lunar far side. The robotic probe is set to begin sample collection before returning its 2 kg (4.4 lb) cargo on 4 June. 4 June – The China National Space Administration's Chang'e 6 spacecraft lifts off from the surface of the far side of the Moon carrying samples of lunar soil and rocks back to Earth. 5 June – Astronomers identify ASKAP J1935+2148, the slowest-spinning neutron star ever recorded, which completes a rotation just once every 54 minutes. 8 June – A paper challenges the public perception and media depictions of large language models like especially ChatGPT, arguing that "bullshitting" in the sense of the book On Bullshit and a fundamentally flawed design are a better approach or terminology for understanding the flaws of these AI architectures or the behavior of the systems based on these as opposed to occasional or frequent "hallucinations". In agreement with many other experts, they find these models are in an "important way indifferent to the truth of their outputs". This notion has also been applied to Perplexity AI that is typically used for generating outputs that are less inaccurate than ChatGPT's – or contain fewer "hallucinations" – and which was scaled up substantially during 2024. An investigation by WIRED reportedly showed the chatbot at times closely paraphrased WIRED stories, and at times summarized stories inaccurately and with minimal attribution.
Sources: en.wikipedia.org
The glial protein most severely affected is FABP5. Another study showed that 100% of hippocampal astrocytes that contain FABP7 also contain FABP5. These data suggest that FABP7+/Gomori-positive astrocytes may play a role in Alzheimer's disease. An altered glial function in this region could compromise the function of dentate gyrus neurons and also the function of axons that terminate in the dentate gyrus. Many such axons originate in the lateral entorhinal cortex, which is the first brain region to show degeneration in Alzheimer's disease. Astrocyte pathology in the hippocampus thus might make a contribution to the pathology of Alzheimer's disease.
Absinthe became associated with violent crimes and social disorder, and one modern writer claims that this trend was spurred by fabricated claims and smear campaigns, which he claims were orchestrated by the temperance movement and the wine industry. One critic claimed:
== Other species == Humanin is the most well-conserved of the mitochondria-derived peptides, found in such diverse species as humans, naked mole rats, and nematodes. Overexpression of humanin in Caenorhabditis elegans has been shown to extend the lifespan of that nematode by increasing autophagy. The rat, Rattus norvegicus, has a gene, rattin (C0HLU6, "Humanin-like protein"), that encodes a 38 amino acid peptide homologous to humanin. The two genes produce cDNAs that show 88% sequence identity. The peptides are 81% identical, with the carboxyl terminal sequence in rattin being 14 amino acids longer than in humanin. Of the 24 amino acids in the rest of the rat sequence, 20 are identical to the amino acids in the human sequence. The mouse MT-RNR2 humanin ortholog is a pseudogene, so no humanin is produced from the mtDNA. However, the nuclear genome harbors (like in humans) many copies of mitochondrial genomes, and one copy of the humanin homolog, Gm20594 (J3QJY3), is actively expressed.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.